about
Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteractionClinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi - data from the German CMN registry.Localisation of bullous pemphigoid antigen 180 (BP180) in cultured human keratinocytes: functionally relevant modification by calcium.Inhibition of Rho A activity causes pemphigus skin blistering.Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction.Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen.The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases.Profibrotic phenotype of conjunctival fibroblasts from mucous membrane pemphigoid.Pemphigoid gestationis: new insights into the pathogenesis lead to novel diagnostic tools.Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoidDevelopment of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus.EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils.Autoreactive T cell responses in pemphigus and pemphigoid.A family with atypical Hailey Hailey disease--is there more to the underlying genetics than ATP2C1?Dissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering diseaseIdentification of a Functional Risk Variant for Pemphigus Vulgaris in the ST18 Gene.Mechanisms of blister induction by autoantibodies.Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1.The 21st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity.Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease.The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseasesThe pathophysiology of bullous pemphigoid.Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases.Research in practice: diagnosis of subepidermal autoimmune bullous disorders.Diagnosis of autoimmune bullous skin diseases.High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B-cell epitope spreading without IgG subclass shifting.Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.Rituximab in severe pemphigus.Immunoadsorption in dermatology.Linear IgA disease: successful application of immunoadsorption and review of the literature.Clinical and immunopathological spectrum of paraneoplastic pemphigus.Epidermolysis bullosa acquisita: what's new?From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.Modern diagnosis of autoimmune blistering skin diseases.Pathogenesis of epidermolysis bullosa acquisita.The diagnosis and treatment of autoimmune blistering skin diseases.
P50
Q24530223-25B2F087-A68E-48BB-8FCE-5C2590265051Q31163409-143B91B0-6397-4FB5-B29A-80B15C57E7E0Q33253777-C3AF2828-C946-4FA4-9E5D-62462C039615Q33264769-AD7D4DBD-0071-4337-A72F-382BB35368FCQ33353295-D765DA01-A8E9-4E7D-B404-55C14E6AE797Q33440138-B578C29E-1DB9-4758-8655-579E1A0A2F2FQ33692698-29C68BF2-954F-4BC9-AA7C-755BF06C423CQ33726907-9747604C-657F-4117-8A95-D30CB1CC0EAAQ34570285-0F431CE8-2D63-4E2E-8193-DB86744C701EQ34655158-B39C4FD0-4A8D-4EE9-BFA6-67BF179BE89FQ34756286-8F0B50AA-20F6-4733-BCE1-70187B7294CBQ34880571-FB62C425-01CA-4BE9-B184-B04950B3A865Q34923028-2394390E-A809-43DD-B871-0114D58154BCQ35001603-4E8DCF06-CC3B-4146-93D3-5B26A69821F7Q35087854-7894AFC0-DB25-476E-BB51-AFB28F792A88Q35172052-AF0E53E3-0371-4655-9F86-9C58BE2E2366Q35250891-DFA58C9E-00D3-44AF-B131-5ECE21377228Q35924242-332792B0-CEC5-42C5-AEE0-D214BB3CAA18Q36009248-2A6DBAFF-EA47-4A57-9557-C3B6DC16DA63Q36307954-0E9CE51B-59B8-408B-8DE3-DFCBF620F934Q36380184-A20A3D67-0B57-4E57-AFFB-D82750716C42Q36604431-B0E94DAD-368E-4B94-86A3-F86BF462217CQ36699586-5A28CAF7-6063-435D-A8BA-AC3E76FC882DQ36728029-C5990D3A-AE39-4E49-8810-73C3FA378DAAQ37038481-F2499CB9-A491-4A68-9572-B118770FF439Q37059099-88BBD111-108B-4689-B092-922A55555CECQ37385117-EA433CDE-2225-437B-B0E5-F121FE808ADFQ37392697-004491F7-0F4C-42BA-8DA7-D3542D4B4735Q37532013-C01FA050-EB04-4DE7-B3E7-90D3C5152C2AQ37555037-91D4FEA0-BE9D-4F20-B58A-3679F8EB2C05Q37589002-F7043686-EDB9-47D9-A3D6-21A71C4605C4Q37598333-EA8C17F4-4BBC-4AA8-90C2-59A95B0C0508Q37668084-CD1E11D0-9D9E-4575-BCF9-01F19F2926D9Q37686984-E35B2D51-2565-4F35-B51B-156A506D197AQ37697887-693317C9-1847-4C25-A207-61DBB96F5991Q37761192-849FB83C-5E32-42B5-BA02-0DAF29CA4A05Q37761193-C2B55AB0-E6CC-4F44-A198-ABF5BEFA44F1Q37780325-3B62AA76-1ABB-4406-91F2-61DD5E48AD6AQ37878649-7BFA9658-62D8-4E85-BE4F-4A3E926508B9Q37895468-B8D08D7E-8CF7-4C3D-8CE9-3ADC21B6D9CD
P50
name
Detlef Zillikens
@ast
Detlef Zillikens
@en
Detlef Zillikens
@nl
type
label
Detlef Zillikens
@ast
Detlef Zillikens
@en
Detlef Zillikens
@nl
prefLabel
Detlef Zillikens
@ast
Detlef Zillikens
@en
Detlef Zillikens
@nl